We are CellField Technologies.
Check us out
The Microphysiological Articular Joint In a Chip (MAJIC) system, at the crux of our groundbreaking initiatives, emerges as a modular cell culture platform poised to redefine the landscape of drug development. With a primary focus on osteoarthritis (OA) and rheumatoid arthritis (RA), MAJOC distinguishes itself by regulating physiological cell phenotypes through nuanced biophysical and biochemical cues, a departure from traditional models reliant on exogenous growth factors. The capability for real-time observations using live-cell microscopy introduces captivating possibilities for understanding the dynamics of joint health.
Beyond the laboratory intricacies, the exploration extends to CellField's strategic vision and services. The company positions itself not merely as a contract research organization (CRO) but as a visionary entity shaping the trajectory of drug development. Strategic collaboration with other ground-breaking companies promises breakthroughs in multiplexed, automated assays. The 151-biomarker analysis matrix we offer, particularly for osteoarthritis, aligns seamlessly with research interests, providing a quantitative and objective approach to biomarker analysis.
